Drug Profile

MVA-BN-HER2

Alternative Names: HER-2 DNA AutoVac; MVA-BN Breast; MVA-BN-HER2; MVA-BN/Her-2/Neu; PX 103.2; PX-1032

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pharmexa
Developer Bavarian Nordic
Class Cancer vaccines
Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Breast cancer

Most Recent Events

15 Sep 2011 Pharmacodynamics data from a preclinical trial in Cancer released by Bavarian Nordic
22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
23 Feb 2009 Bavarian Nordic acquires patent rights to PX 1032 from Pharmexa

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com